Your browser doesn't support javascript.
Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.
Pulvirenti, Federica; Milito, Cinzia; Cinetto, Francesco; Fernandez Salinas, Ane; Terreri, Sara; Piano Mortari, Eva; Auria, Stefania; Soccodato, Valentina; Miriam, Lichtner; Nicastri, Emanuele; Vincenzi, Laura; Carsetti, Rita; D'Offizi, Gianpiero; Quinti, Isabella.
  • Pulvirenti F; Primary Immune Deficiencies Unit, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy.
  • Milito C; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Cinetto F; Department of Medicine-DIMED, University of Padova, and Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy.
  • Fernandez Salinas A; Department of Molecular Medicine, Sapienza University of Rome and Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Terreri S; Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Piano Mortari E; Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Auria S; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Soccodato V; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Miriam L; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.
  • Nicastri E; Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy.
  • Vincenzi L; National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.
  • Carsetti R; POIT-INMI Spallanzani Infectious Diseases/Hepatology Unit, Rome, Italy.
  • D'Offizi G; Department of Molecular Medicine, Sapienza University of Rome and Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Quinti I; POIT-INMI Spallanzani Infectious Diseases/Hepatology Unit, Rome, Italy.
J Infect Dis ; 225(5): 820-824, 2022 03 02.
Article in English | MEDLINE | ID: covidwho-1722476
ABSTRACT

BACKGROUND:

Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.

METHODS:

We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.

RESULTS:

Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.

CONCLUSIONS:

The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Common Variable Immunodeficiency / Primary Immunodeficiency Diseases / SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Common Variable Immunodeficiency / Primary Immunodeficiency Diseases / SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis